Who are Linezolid (LZD)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sivextro 200 milligrams Oral Tablet, Oral Suspension Tedizolid Phosphate, linezolid (Zyvox), Tedizolid IV, Tedizolid PO, Linezolid antimicrobial-lock solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/linezolid-lzd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Linezolid (LZD) — Competitive Intelligence Brief

Linezolid (LZD) (Linezolid (LZD)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit (23S rRNA) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Linezolid (LZD) (Linezolid (LZD)) — Wuhan Pulmonary Hospital. Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Linezolid (LZD) TARGET	Linezolid (LZD)	Wuhan Pulmonary Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Sivextro 200 milligrams Oral Tablet	Sivextro 200 milligrams Oral Tablet	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 70S ribosome (peptidyl transferase center)
Oral Suspension Tedizolid Phosphate	Oral Suspension Tedizolid Phosphate	Merck Sharp & Dohme LLC	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
linezolid (Zyvox)	linezolid (Zyvox)	Pfizer	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Tedizolid IV	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Tedizolid PO	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
University of Southern California · 2 drugs in this class
Arpida AG · 2 drugs in this class
Pfizer · 1 drug in this class
Shenzhen Third People's Hospital · 1 drug in this class
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
Wuhan Pulmonary Hospital · 1 drug in this class
Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Linezolid (LZD) — Competitive Intelligence Brief. https://druglandscape.com/ci/linezolid-lzd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab